特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
926768

バイオシミラー市場 - 世界の業界分析、規模、シェア、成長、動向、予測

Biosimilars Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

出版日: | 発行: Transparency Market Research | ページ情報: 英文 232 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=106.45円
バイオシミラー市場 - 世界の業界分析、規模、シェア、成長、動向、予測
出版日: 2020年01月08日
発行: Transparency Market Research
ページ情報: 英文 232 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界のバイオシミラー市場について調査し、市場の動向と予測、市場規模、主要参入企業、地域別動向についてまとめています。

第1章 序論

第2章 仮定と調査方法

第3章 調査結果

第4章 エグゼクティブサマリー

第5章 市場概要

  • 定義
  • 市場指標
  • 市場動向
    • 促進因子
    • 阻害因子
    • 機会

第6章 市場見通し

  • 市場分析と予測
  • 市場見通し
  • 市場参入障壁
  • バイオシミラー導入促進因子
  • パイプライン分析
  • 法規制シナリオ
  • 主な業界発展

第7章 市場分析と予測:製品別

  • イントロダクション
  • 市場価値予測
    • 組み換えグリコシル化タンパク質
    • 組み換え非グリコシル化タンパク質
    • 組み換えペプチド
  • 市場の魅力度

第8章 市場分析と予測:適応別

  • イントロダクション
  • 市場価値予測
    • 慢性疾患
    • 腫瘍
    • 自己免疫疾患
    • 感染症
    • 血液疾患
    • 成長ホルモン欠損症
    • その他
  • 市場の魅力度

第9章 市場分析と予測:地域別

  • 地域別見通し
  • 世界のシナリオ
  • イントロダクション
  • 市場価値予測
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力度

第10章 北米

第11章 欧州

第12章 アジア太平洋地域

第13章 ラテンアメリカ

第14章 中東・アフリカ

第15章 競合環境

  • 競合マトリクス
  • 市場シェア分析
  • 企業プロファイル
図表

List of Tables

  • Table 01: Pipeline Analysis - Biosimilars
  • Table 02: Global Biosimilars Market Value (US$ Mn) Forecast, by Product, 2017-2027
  • Table 03: Global Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Glycosylated Proteins, 2017-2027
  • Table 04: Global Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Non-glycosylated Proteins, 2017-2027
  • Table 05: Global Biosimilars Market Value (US$ Mn) Forecast, by Indication, 2017-2027
  • Table 06: Global Biosimilars Market Value (US$ Mn) Forecast, by Region, 2017-2027
  • Table 07: North America Biosimilars Market Value (US$ Mn) Forecast, by Country, 2017-2027
  • Table 08: North America Biosimilars Market Value (US$ Mn) Forecast, by Product Type, 2017-2027
  • Table 09: North America Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Glycosylated Proteins, 2017-2027
  • Table 10: North America Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Non-glycosylated Proteins, 2017-2027
  • Table 11: North America Biosimilars Market Value (US$ Mn) Forecast, by Indication, 2017-2027
  • Table 12: Europe Biosimilars Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 13: Europe Biosimilars Market Value (US$ Mn) Forecast, by Product Type, 2017-2027
  • Table 14: Europe Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Glycosylated Proteins, 2017-2027
  • Table 15: Europe Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Non-glycosylated Proteins, 2017-2027
  • Table 16: Europe Biosimilars Market Value (US$ Mn) Forecast, by Indication, 2017-2027
  • Table 17: Asia Pacific Biosimilars Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 18: Asia Pacific Biosimilars Market Value (US$ Mn) Forecast, by Product, 2017-2027
  • Table 19: Asia Pacific Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Glycosylated Proteins, 2017-2027
  • Table 20: Asia Pacific Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Non-glycosylated Proteins, 2017-2027
  • Table 21: Asia Pacific Biosimilars Market Value (US$ Mn) Forecast, by Indication, 2017-2027
  • Table 22: Latin America Biosimilars Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 23: Latin America Biosimilars Market Value (US$ Mn) Forecast, by Product, 2017-2027
  • Table 24: Latin America Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Glycosylated Proteins, 2017-2027
  • Table 25: Latin America Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Non-glycosylated Proteins, 2017-2027
  • Table 26: Latin America Biosimilars Market Value (US$ Mn) Forecast, by Indication, 2017-2027
  • Table 27: Middle East & Africa Biosimilars Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 28: Middle East & Africa Biosimilars Market Value (US$ Mn) Forecast, by Product, 2017-2027
  • Table 29: Middle East & Africa Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Glycosylated Proteins, 2017-2027
  • Table 30: Middle East & Africa Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Non-glycosylated Proteins, 2017-2027
  • Table 31: Middle East & Africa Biosimilars Market Value (US$ Mn) Forecast, by Indication, 2017-2027

List of Figures

  • Figure 01: Global Biosimilars Market Snapshot
  • Figure 02: Global Biosimilars Market Value (US$ Mn) by Region, 2019 and 2027
  • Figure 03: Global Biosimilars Market Value (US$ Mn) Forecast, 2017-2027
  • Figure 04: Global Biosimilars Market Value Share (%), by Product (2019)
  • Figure 05: Global Biosimilars Market Value Share (%), by Indication (2019)
  • Figure 06: Global Biosimilars Market Value Share (%), by Region (2019)
  • Figure 07: Entry Barriers to Biosimilars Market
  • Figure 08: Factors Driving the Adoption of Biosimilars
  • Figure 09: Biosimilar Approval Process - US
  • Figure 10: Data Requirements for Biosimilar Approval in Europe
  • Figure 11: Regulations for Biosimilar Approval in Japan
  • Figure 12: Regulations for Biosimilar Approval in India
  • Figure 13: Regulations for Biosimilar Approval in Brazil
  • Figure 14: Regulations for Biosimilar Approval in Saudi Arabia
  • Figure 15: Biosimilars Market - Key Product Launches
  • Figure 16: Global Biosimilars Market Value Share Analysis, by Product, 2018 and 2027
  • Figure 17: Global Biosimilars Market Value Share Analysis, by Recombinant Glycosylated Proteins, 2018 and 2027
  • Figure 18: Global Biosimilars Market Value Share Analysis, by Recombinant Non-glycosylated Proteins, 2018 and 2027
  • Figure 19: Global Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Glycosylated Proteins, 2017-2027
  • Figure 20: Global Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Non-glycosylated Proteins, 2017-2027
  • Figure 21: Global Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Peptides, 2017-2027
  • Figure 22: Global Biosimilars Market Value (US$ Mn) Forecast, by Monoclonal Antibodies, 2017-2027
  • Figure 23: Global Biosimilars Market Value (US$ Mn) Forecast, by Erythropoietin, 2017-2027
  • Figure 24: Global Biosimilars Market Value (US$ Mn) Forecast, by Others, 2017-2027
  • Figure 25: Global Biosimilars Market Value (US$ Mn) Forecast, by Insulin, 2017-2027
  • Figure 26: Global Biosimilars Market Value (US$ Mn) Forecast, by Granulocyte Colony Stimulating Factor, 2017-2027
  • Figure 27: Global Biosimilars Market Value (US$ Mn) Forecast, by Recombinant Human Growth Factor, 2017-2027
  • Figure 28: Global Biosimilars Market Value (US$ Mn) Forecast, by Interferons, 2017-2027
  • Figure 29: Global Biosimilars Market Attractiveness, by Product, 2019?2027
  • Figure 30: Global Biosimilars Market Attractiveness, by Recombinant Glycosylated Proteins, 2019?2027
  • Figure 31: Global Biosimilars Market Attractiveness, by Recombinant Non-glycosylated Proteins, 2019?2027
  • Figure 32: Global Biosimilars Market Value Share Analysis, by Indication, 2018 and 2027
  • Figure 33: Global Biosimilars Market Value (US$ Mn) Forecast, by Chronic Diseases, 2017-2027
  • Figure 34: Global Biosimilars Market Value (US$ Mn) Forecast, by Oncology, 2017-2027
  • Figure 35: Global Biosimilars Market Value (US$ Mn) Forecast, by Autoimmune Diseases, 2017-2027
  • Figure 36: Global Biosimilars Market Value (US$ Mn) Forecast, by Infectious Diseases, 2017-2027
  • Figure 37: Global Biosimilars Market Value (US$ Mn) Forecast, by Blood Disorders, 2017-2027
  • Figure 38: Global Biosimilars Market Value (US$ Mn) Forecast, by Growth Hormone Deficiency, 2017-2027
  • Figure 39: Global Biosimilars Market Value (US$ Mn) Forecast, by Others, 2017-2027
  • Figure 40: Global Biosimilars Market Attractiveness, by Indication, 2019?2027
  • Figure 41: Global Biosimilars Market: Regional Outlook
  • Figure 42: Global Biosimilars Market Value Share Analysis, by Region, 2018 and 2027
  • Figure 43: Global Biosimilars Market Attractiveness Analysis, by Region, 2019-2027
  • Figure 44: North America Biosimilars Market Value (US$ Mn) Forecast, 2017-2027
  • Figure 45: North America Biosimilars Market Value Share Analysis, by Country, 2018 and 2027
  • Figure 46: North America Biosimilars Market Value Share Analysis, by Product, 2018 and 2027
  • Figure 47: North America Biosimilars Market Value Share Analysis, by Recombinant Glycosylated Proteins, 2018 and 2027
  • Figure 48: North America Biosimilars Market Value Share Analysis, by Recombinant Non-glycosylated Proteins, 2018 and 2027
  • Figure 49: North America Biosimilars Market Value Share Analysis, by Indication, 2018 and 2027
  • Figure 50: North America Biosimilars Market Attractiveness, by Product, 2019?2027
  • Figure 51: North America Biosimilars Market Attractiveness, by Recombinant Glycosylated Proteins, 2019?2027
  • Figure 52: North America Biosimilars Market Attractiveness, by Recombinant Non-glycosylated Proteins, 2019?2027
  • Figure 53: North America Biosimilars Market Attractiveness, by Indication, 2019?2027
  • Figure 54: North America Biosimilars Market Attractiveness, by Country, 2019?2027
  • Figure 55: Europe Biosimilars Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2027
  • Figure 56: Europe Biosimilars Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 57: Europe Biosimilars Market Value Share Analysis, by Product, 2018 and 2027
  • Figure 58: Europe Biosimilars Market Value Share Analysis, by Recombinant Glycosylated Proteins, 2018 and 2027
  • Figure 59: Europe Biosimilars Market Value Share Analysis, by Recombinant Non-glycosylated Proteins, 2018 and 2027
  • Figure 60: Europe Biosimilars Market Value Share Analysis, by Indication, 2018 and 2027
  • Figure 61: Europe Biosimilars Market Attractiveness, by Product, 2019?2027
  • Figure 62: Europe Biosimilars Market Attractiveness, by Recombinant Glycosylated Proteins, 2019?2027
  • Figure 63: Europe Biosimilars Market Attractiveness, by Recombinant Non-glycosylated Proteins, 2019?2027
  • Figure 64: Europe Biosimilars Market Attractiveness, by Indication, 2019?2027
  • Figure 65: Europe Biosimilars Market Attractiveness, by Country/Sub-region, 2019?2027
  • Figure 66: Asia Pacific Biosimilars Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2027
  • Figure 67: Asia Pacific Biosimilars Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 68: Asia Pacific Biosimilars Market Value Share Analysis, by Product, 2018 and 2027
  • Figure 69: Asia Pacific Biosimilars Market Value Share Analysis, by Recombinant Glycosylated Proteins, 2018 and 2027
  • Figure 70: Asia Pacific Biosimilars Market Value Share Analysis, by Recombinant Non-glycosylated Proteins, 2018 and 2027
  • Figure 71: Asia Pacific Biosimilars Market Value Share Analysis, by Indication, 2018 and 2027
  • Figure 72: Asia Pacific Biosimilars Market Attractiveness, by Product, 2019?2027
  • Figure 73: Asia Pacific Biosimilars Market Attractiveness, by Recombinant Glycosylated Proteins, 2019?2027
  • Figure 74: Asia Pacific Biosimilars Market Attractiveness, by Recombinant Non-glycosylated Proteins, 2019?2027
  • Figure 75: Asia Pacific Biosimilars Market Attractiveness, by Indication, 2019?2027
  • Figure 76: Asia Pacific Biosimilars Market Attractiveness, by Country/Sub-region, 2019?2027
  • Figure 77: Latin America Biosimilars Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2027
  • Figure 78: Latin America Biosimilars Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 79: Latin America Biosimilars Market Value Share Analysis, by Product, 2018 and 2027
  • Figure 80: Latin America Biosimilars Market Value Share Analysis, by Recombinant Glycosylated Proteins, 2018 and 2027
  • Figure 81: Latin America Biosimilars Market Value Share Analysis, by Recombinant Non-glycosylated Proteins, 2018 and 2027
  • Figure 82: Latin America Biosimilars Market Value Share Analysis, by Indication, 2018 and 2027
  • Figure 83: Latin America Biosimilars Market Attractiveness, by Product, 2019?2027
  • Figure 84: Latin America Biosimilars Market Attractiveness, by Recombinant Glycosylated Proteins, 2019?2027
  • Figure 85: Latin America Biosimilars Market Attractiveness, by Recombinant Non-glycosylated Proteins, 2019?2027
  • Figure 86: Latin America Biosimilars Market Attractiveness, by Indication, 2019?2027
  • Figure 87: Latin America Biosimilars Market Attractiveness, by Country/Sub-region, 2019?2027
  • Figure 88: Middle East & Africa Biosimilars Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2027
  • Figure 89: Middle East & Africa Biosimilars Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 90: Middle East & Africa Biosimilars Market Value Share Analysis, by Product, 2018 and 2027
  • Figure 91: Middle East & Africa Biosimilars Market Value Share Analysis, by Recombinant Glycosylated Proteins, 2018 and 2027
  • Figure 92: Middle East & Africa Biosimilars Market Value Share Analysis, by Recombinant Non-glycosylated Proteins, 2018 and 2027
  • Figure 93: Middle East & Africa Biosimilars Market Value Share Analysis, by Indication, 2018 and 2027
  • Figure 94: Middle East & Africa Biosimilars Market Attractiveness, by Product, 2019?2027
  • Figure 95: Middle East & Africa Biosimilars Market Attractiveness, by Recombinant Glycosylated Proteins, 2019?2027
  • Figure 96: Middle East & Africa Biosimilars Market Attractiveness, by Recombinant Non-glycosylated Proteins, 2019?2027
  • Figure 97: Middle East & Africa Biosimilars Market Attractiveness, by Indication, 2019?2027
  • Figure 98: Middle East & Africa Biosimilars Market Attractiveness, by Country/Sub-region, 2019?2027
  • Figure 99: Global Biosimilars Market Share Analysis, by Company (2018)
目次
Product Code: TMRGL118

Title:
Biosimilars Market (Product: Recombinant Glycosylated Proteins [Monoclonal Antibodies, Erythropoietin, and Others], Recombinant Non-glycosylated Proteins [Insulin, Granulocyte Colony Stimulating Factor, Recombinant Human Growth Factor, and Interferons], and Recombinant Peptides; and Indication: Chronic Diseases, Oncology, Autoimmune Diseases, Infectious Diseases, Blood Disorders, Growth Hormone Deficiency, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027.

Biosimilars Market - Scope of the Report

TMR'S report on the global biosimilars market studies the past as well as current growth trends and opportunities to gain valuable insights of the same indicators for the said market during the forecast period of 2019 to 2027. The report provides the overall market revenue of the global biosimilars market for the period 2017-2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global biosimilars market for the forecast period.

The report has been prepared after an extensive research. Primary research involves bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involves referring to key players' product literature, annual reports, press releases, and relevant documents to understand the global biosimilars market.

Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have also employed a combination of the top-down and bottom-up approaches to study various phenomena in the global biosimilars market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Additionally, the report sheds light on the changing competitive dynamics in the global biosimilars market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the global biosimilars market. The next section of the global biosimilars report highlights the USPs, which include regulatory scenarios for biosimilars globally, Biosimilars pipeline analysis, and potential product launches in the global biosimilars market.

The report delves into the competitive landscape of the global biosimilars market. Key players operating in the global biosimilars market have been identified, and each one of these has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players profiled in the global biosimilars market report.

Key Questions Answered in Biosimilars Market Report

What is the sales/revenue generated by biosimilar products across all regions during the forecast period?

What are the key trends in the biosimilars market?

What are the major drivers, restraints, and opportunities in the market?

In which region is the biosimilars market set to expand at the fastest CAGR during the forecast period?

Which segment will have the highest revenue globally in 2027 and which product segment will expand at the fastest CAGR during the forecast period?

Biosimilars Market - Research Objectives and Research Approach

The comprehensive report on the global biosimilars market begins with an overview of the said market, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives of this study and healthcare compliances laid down by accredited agencies in the purview of research in the biosimilars market. It is followed by market introduction, market dynamics, and an overview of the biosimilars market, which includes TMR analysis of market drivers, restraints, and trends affecting the growth of the market. Furthermore, Y-o-Y analysis with elaborate insights has been provided to understand the Y-o-Y trends of the biosimilars market. The next section of the biosimilars report highlights the USPs, which include regulatory scenarios for biosimilars globally, biosimilars pipeline analysis, and key product launches in the global market.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section further divided into small sections. The entire report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

Revenue generated by key biosimilars market manufacturers have been mapped to ascertain the size of the global biosimilars market in terms of value. The forecast presented here assesses the total revenue generated in the biosimilars market. In order to provide an accurate forecast, we initiated by sizing up the current biosimilars market with the help of the parent market.

The report analyzes the biosimilars market in terms of product, indication, and region. Key segments under each criteria have been studied at length, and the market share for each of these at the end of 2027 has been provided. These valuable insights would help market stakeholders in making informed business decisions for investments in the biosimilars market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Acronyms

3. Research Methodology

4. Executive Summary: Global Biosimilars Market

5. Market Overview

  • 5.1. Definition
  • 5.2. Market Indicators
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunities

6. Market Outlook

  • 6.1. Global Biosimilars Market Analysis and Forecast, 2017-2027
  • 6.2. Global Biosimilars Market Outlook
  • 6.3. Entry Barriers to Biosimilars Market
  • 6.4. Factors Driving the Adoption of Biosimilars
  • 6.5. Pipeline Analysis
  • 6.6. Regulatory Scenario Assessment
  • 6.7. Key Industry Developments

7. Global Biosimilars Market Analysis and Forecast, by Product

  • 7.1. Introduction
  • 7.2. Biosimilars Market Value Forecast, by Product, 2017-2027
    • 7.2.1. Recombinant Glycosylated Proteins
      • 7.2.1.1. Monoclonal Antibodies
      • 7.2.1.2. Erythropoietin
      • 7.2.1.3. Others
    • 7.2.2. Recombinant Non-glycosylated Proteins
      • 7.2.2.1. Insulin
      • 7.2.2.2. Granulocyte Colony Stimulating Factor
      • 7.2.2.3. Recombinant Human Growth Factor
      • 7.2.2.4. Interferons
    • 7.2.3. Recombinant Peptides
  • 7.3. Market Attractiveness, by Product

8. Global Biosimilars Market Analysis and Forecast, by Indication

  • 8.1. Introduction
  • 8.2. Biosimilars Market Value Forecast, by Indication, 2017-2027
    • 8.2.1. Chronic Diseases
    • 8.2.2. Oncology
    • 8.2.3. Autoimmune Diseases
    • 8.2.4. Infectious Diseases
    • 8.2.5. Blood Disorders
    • 8.2.6. Growth Hormone Deficiency
    • 8.2.7. Others
  • 8.3. Market Attractiveness By Material

9. Global Biosimilars Market Analysis and Forecast, by Region

  • 9.1. Regional Outlook
  • 9.2. Global Scenario
  • 9.3. Introduction
  • 9.4. Biosimilars Market Value Forecast, by Region
    • 9.4.1. North America
    • 9.4.2. Europe
    • 9.4.3. Asia Pacific
    • 9.4.4. Latin America
    • 9.4.5. Middle East & Africa
  • 9.5. Market Attractiveness, by Region

10. North America Biosimilars Market Analysis and Forecast

  • 10.1. Key Findings
  • 10.2. North America Biosimilars Market Value Forecast, by Product, 2017-2027
    • 10.2.1. Recombinant Glycosylated Proteins
      • 10.2.1.1. Monoclonal Antibodies
      • 10.2.1.2. Erythropoietin
      • 10.2.1.3. Others
    • 10.2.2. Recombinant Non-glycosylated Proteins
      • 10.2.2.1. Insulin
      • 10.2.2.2. Granulocyte Colony Stimulating Factor
      • 10.2.2.3. Recombinant Human Growth Factor
      • 10.2.2.4. Interferons
    • 10.2.3. Recombinant Peptides
  • 10.3. North America Biosimilars Market Value Forecast, by Indication, 2017-2027
    • 10.3.1. Chronic Diseases
    • 10.3.2. Oncology
    • 10.3.3. Autoimmune Diseases
    • 10.3.4. Infectious Diseases
    • 10.3.5. Blood Disorders
    • 10.3.6. Growth Hormone Deficiency
    • 10.3.7. Others
  • 10.4. North America Biosimilars Market Value Forecast, by Country, 2017-2027
    • 10.4.1. U.S.
    • 10.4.2. Canada
  • 10.5. North America Biosimilars Market Attractiveness Analysis
    • 10.5.1. By Product
    • 10.5.2. By Indication
    • 10.5.3. By Country

11. Europe Biosimilars Market Analysis and Forecast

  • 11.1. Key Findings
  • 11.2. Europe Biosimilars Market Value Forecast, by Product, 2017-2027
    • 11.2.1. Recombinant Glycosylated Proteins
      • 11.2.1.1. Monoclonal Antibodies
      • 11.2.1.2. Erythropoietin
      • 11.2.1.3. Others
    • 11.2.2. Recombinant Non-glycosylated Proteins
      • 11.2.2.1. Insulin
      • 11.2.2.2. Granulocyte Colony Stimulating Factor
      • 11.2.2.3. Recombinant Human Growth Factor
      • 11.2.2.4. Interferons
    • 11.2.3. Recombinant Peptides
  • 11.3. Europe Biosimilars Market Value Forecast, by Indication, 2017-2027
    • 11.3.1. Chronic Diseases
    • 11.3.2. Oncology
    • 11.3.3. Autoimmune Diseases
    • 11.3.4. Infectious Diseases
    • 11.3.5. Blood Disorders
    • 11.3.6. Growth Hormone Deficiency
    • 11.3.7. Others
  • 11.4. Europe Biosimilars Market Value Forecast, by Country/Sub-region, 2017-2027
    • 11.4.1. U.K.
    • 11.4.2. Germany
    • 11.4.3. France
    • 11.4.4. Italy
    • 11.4.5. Spain
    • 11.4.6. Rest of Europe
  • 11.5. Europe Biosimilars Market Attractiveness Analysis
    • 11.5.1. By Product
    • 11.5.2. By Indication
    • 11.5.3. By Country/Sub-region

12. Asia Pacific Biosimilars Market Analysis and Forecast

  • 12.1. Key Findings
  • 12.2. Asia Pacific Biosimilars Market Value Forecast, by Product, 2017-2027
    • 12.2.1. Recombinant Glycosylated Proteins
      • 12.2.1.1. Monoclonal Antibodies
      • 12.2.1.2. Erythropoietin
      • 12.2.1.3. Others
    • 12.2.2. Recombinant Non-glycosylated Proteins
      • 12.2.2.1. Insulin
      • 12.2.2.2. Granulocyte Colony Stimulating Factor
      • 12.2.2.3. Recombinant Human Growth Factor
      • 12.2.2.4. Interferons
    • 12.2.3. Recombinant Peptides
  • 12.3. Asia Pacific Biosimilars Market Value Forecast, by Indication, 2017-2027
    • 12.3.1. Chronic Diseases
    • 12.3.2. Oncology
    • 12.3.3. Autoimmune Diseases
    • 12.3.4. Infectious Diseases
    • 12.3.5. Blood Disorders
    • 12.3.6. Growth Hormone Deficiency
    • 12.3.7. Others
  • 12.4. Asia Pacific Biosimilars Market Value Forecast, by Country/Sub-region, 2017-2027
    • 12.4.1. China
    • 12.4.2. India
    • 12.4.3. Japan
    • 12.4.4. Australia & New Zealand
    • 12.4.5. Rest of Asia Pacific
  • 12.5. Asia Pacific Biosimilars Market Attractiveness Analysis
    • 12.5.1. By Product
    • 12.5.2. By Indication
    • 12.5.3. By Country/Sub-region

13. Latin America Biosimilars Market Analysis and Forecast

  • 13.1. Key Findings
  • 13.2. Latin America Biosimilars Market Value Forecast, by Product, 2017-2027
    • 13.2.1. Recombinant Glycosylated Proteins
      • 13.2.1.1. Monoclonal Antibodies
      • 13.2.1.2. Erythropoietin
      • 13.2.1.3. Others
    • 13.2.2. Recombinant Non-glycosylated Proteins
      • 13.2.2.1. Insulin
      • 13.2.2.2. Granulocyte Colony Stimulating Factor
      • 13.2.2.3. Recombinant Human Growth Factor
      • 13.2.2.4. Interferons
    • 13.2.3. Recombinant Peptides
  • 13.3. Latin America Biosimilars Market Value Forecast, by Indication, 2017-2027
    • 13.3.1. Chronic Diseases
    • 13.3.2. Oncology
    • 13.3.3. Autoimmune Diseases
    • 13.3.4. Infectious Diseases
    • 13.3.5. Blood Disorders
    • 13.3.6. Growth Hormone Deficiency
    • 13.3.7. Others
  • 13.4. Latin America Biosimilars Market Value Forecast, by Country/Sub-region, 2017-2027
    • 13.4.1. Brazil
    • 13.4.2. Mexico
    • 13.4.3. Rest of Latin America
  • 13.5. Latin America Biosimilars Market Attractiveness Analysis
    • 13.5.1. By Product
    • 13.5.2. By Indication
    • 13.5.3. By Country/Sub-region

14. Middle East & Africa Biosimilars Market Analysis and Forecast

  • 14.1. Key Findings
  • 14.2. Middle East & Africa Biosimilars Market Value Forecast, by Product, 2017-2027
    • 14.2.1. Recombinant Glycosylated Proteins
      • 14.2.1.1. Monoclonal Antibodies
      • 14.2.1.2. Erythropoietin
      • 14.2.1.3. Others
    • 14.2.2. Recombinant Non-glycosylated Proteins
      • 14.2.2.1. Insulin
      • 14.2.2.2. Granulocyte Colony Stimulating Factor
      • 14.2.2.3. Recombinant Human Growth Factor
      • 14.2.2.4. Interferons
    • 14.2.3. Recombinant Peptides
  • 14.3. Middle East & Africa Biosimilars Market Value Forecast, by Indication, 2017-2027
    • 14.3.1. Chronic Diseases
    • 14.3.2. Oncology
    • 14.3.3. Autoimmune Diseases
    • 14.3.4. Infectious Diseases
    • 14.3.5. Blood Disorders
    • 14.3.6. Growth Hormone Deficiency
    • 14.3.7. Others
  • 14.4. Middle East & Africa Biosimilars Market Value Forecast, by Country/Sub-region, 2017-2027
    • 14.4.1. GCC Countries
    • 14.4.2. South Africa
    • 14.4.3. Rest of Middle East & Africa
  • 14.5. Middle East & Africa Biosimilars Market Attractiveness Analysis
    • 14.5.1. By Product
    • 14.5.2. By Indication
    • 14.5.3. By Country/Sub-region

15. Competition Landscape

  • 15.1. Competition Matrix
  • 15.2. Market Share Analysis, by Company, 2018
  • 15.3. Company Profiles
    • 15.3.1. Pfizer, Inc.
      • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.1.2. Financial Overview
      • 15.3.1.3. Product Portfolio
      • 15.3.1.4. Strategic Overview
      • 15.3.1.5. SWOT Analysis
    • 15.3.2. Intas Pharmaceuticals Ltd.
      • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.2.2. Financial Overview
      • 15.3.2.3. Product Portfolio
      • 15.3.2.4. Strategic Overview
      • 15.3.2.5. SWOT Analysis
    • 15.3.3. Biocon
      • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.3.2. Financial Overview
      • 15.3.3.3. Product Portfolio
      • 15.3.3.4. Strategic Overview
      • 15.3.3.5. SWOT Analysis
    • 15.3.4. Dr. Reddy's Laboratories Ltd.
      • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.4.2. Financial Overview
      • 15.3.4.3. Product Portfolio
      • 15.3.4.4. Strategic Overview
      • 15.3.4.5. SWOT Analysis
    • 15.3.5. Teva Pharmaceutical Industries Ltd.
      • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.5.2. Financial Overview
      • 15.3.5.3. Product Portfolio
      • 15.3.5.4. Strategic Overview
      • 15.3.5.5. SWOT Analysis
    • 15.3.6. Sandoz International GmbH (A Novartis Division)
      • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.6.2. Financial Overview
      • 15.3.6.3. Product Portfolio
      • 15.3.6.4. Strategic Overview
      • 15.3.6.5. SWOT Analysis
    • 15.3.7. Celltrion Inc.
      • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.7.2. Financial Overview
      • 15.3.7.3. Product Portfolio
      • 15.3.7.4. Strategic Overview
      • 15.3.7.5. SWOT Analysis
    • 15.3.8. Amgen, Inc.
      • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.8.2. Financial Overview
      • 15.3.8.3. Product Portfolio
      • 15.3.8.4. Strategic Overview
      • 15.3.8.5. SWOT Analysis
    • 15.3.9. STADA Arzneimittel AG
      • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.9.2. Financial Overview
      • 15.3.9.3. Product Portfolio
      • 15.3.9.4. Strategic Overview
      • 15.3.9.5. SWOT Analysis
    • 15.3.10. Apotex Inc. (Apobiologix)
      • 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.10.2. Financial Overview
      • 15.3.10.3. Product Portfolio
      • 15.3.10.4. Strategic Overview
      • 15.3.10.5. SWOT Analysis
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.